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Abstract 
Background: Treatment of bacterial biofilms are difficult and in many cases, expensive. Bacterial biofilms are natu-
rally more resilient to antimicrobial agents than their free-living planktonic counterparts, rendering the community 
growth harder to control. The present work described the risks of long-term use of an important alternative antimicro-
bial, silver nanoparticles (NAg), for the first time, on the dominant mode of bacterial growth.
Results: NAg could inhibit the formation as well as eradicating an already grown biofilm of Pseudomonas aeruginosa, 
a pathogen notorious for its resilience to antibiotics. The biofilm-forming bacterium however, evolved a reduced sen-
sitivity to the nanoparticle. Evidence suggests that survival is linked to the development of persister cells within the 
population. A similar adaptation was also seen upon prolonged exposures to ionic silver  (Ag+). The persister popula-
tion resumed normal growth after subsequent passage in the absence of silver, highlighting the potential risks of 
recurrent infections with long-term NAg (and  Ag+) treatments of biofilm growth. The present study further observed 
a potential silver/antibiotic cross-resistance, whereby NAg (as well as  Ag+) could not eradicate an already growing 
gentamicin-resistant P. aeruginosa biofilm. The phenomena is thought to result from the hindered biofilm penetration 
of the silver species. In contrast, both silver formulations inhibited biofilm formation of the resistant strain, presenting 
a promising avenue for the control of biofilm-forming antibiotic-resistant bacteria.
Conclusion: The findings signify the importance to study the nanoparticle adaptation phenomena in the bio-
film mode of bacterial growth, which are apparently unique to those already reported with the planktonic growth 
counterparts. This work sets the foundation for future studies in other globally significant bacterial pathogens when 
present as biofilms. Scientifically based strategies for management of pathogenic growth is necessary, particularly in 
this era of increasing antibiotic resistance.
Keywords: Nanoparticle, Antibiotic resistance, Pseudomonas, Pathogen, Biofilm, Persistence
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Biofilms, a surface-attached growth of microbes, are the 
dominant form of bacterial growth [1]. Bacterial bio-
films are the leading cause of many chronic and persis-
tent infections [2]. Their growth accounts for more than 
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commonly found on medical devices and prostheses, 
such as intravenous and urinary catheters as well as car-
diac pace makers, on wounds, even on heart valves [2, 
3]. Treatment of biofilm-related infections is indeed a 
challenge. Unlike their planktonic counterparts, bacteria 
in biofilms are protected in a self-produced polymeric 
matrix, referred to as extracellular polymeric substance 
(EPS), rendering them resilient to antibiotics (Fig.  1A) 
[1]. This protective matrix acts as a barrier, significantly 
reducing the penetration of antibiotics, such that the 
concentration reaching the bacterial biomass is at sub-
therapeutic levels and therefore ineffective [4, 5]. Bacte-
ria in a clinically-relevant biofilm can generate signaling 
molecules (the auto-inducers) that activate the expres-
sion of a number of virulence genes, toxins as well as 
the EPS components, to safeguard the entire community 
from antibacterial agents [6, 7]. Bacteria in biofilms can 
also transfer antibiotic resistance genes to each other and 
at higher frequencies than their planktonic counterparts; 
with studies, for instance, reporting the transfer of ESBL 
genes-harbouring plasmids (the genes encode extended-
spectrum β-lactamase enzymes that confer resistance to 
β-lactam antibiotics) in Klebsiella pneumoniae biofilm 
[8]. Collectively, these mechanisms help to protect bio-
film cells from antibiotics and other stressors. This has 
prompted research on non-antibiotic therapy options 
for biofilm growth inhibition and eradication, with one 
of the major alternatives being the development of the 
broad spectrum antibacterial nanoparticles, nanosilver 
(NAg) [9].
NAg exhibit potent microbiological activities. The 
nanoparticle has shown efficacy on Gram-positive and 
Gram-negative bacteria, including those that cause noso-
comial infections such as Staphylococcus aureus and K. 
pneumoniae, and indeed, at a growth inhibiting and even 
cell-killing concentrations that are non-toxic to human 
cells, as shown by many studies [10–13]. NAg, upon con-
tact with an aqueous environment, will undergo oxidative 
dissolution and release silver ions  (Ag+) [14, 15]. Studies 
have shown that both the leached soluble silver and the 
solid silver particulates that remain after leaching con-
tribute to the overall toxicity of the nanoparticle [16, 17]. 
Unlike the single mode of action of most antibiotics, NAg 
attacks multiple targets in bacteria, from the cell enve-
lope peptidoglycan and phospholipid molecules [18], the 
respiratory chain enzymes in the inner membrane, to dis-
ruption of iron-sulfur clusters that are present in many 
enzymes [19]. The latter is thought to lead to the release 
of the Fenton-active  Fe2+ ions, which in turn reacts with 
the cellular peroxides to generate reactive oxygen species 
(ROS), one of the established mechanisms of NAg toxic-
ity [18]. NAg is more widely used than the ionic form of 
silver, with the nanoparticle enabling a controlled release 
of  Ag+, and therefore, a more sustained antibacterial 
activity [20]. The nanoparticles have also shown synergis-
tic effects and enhance the antibacterial activity of con-
ventional antibiotics, including on multidrug resistant 
bacteria [11, 21, 22].
There was a common perception that development of 
bacterial resistance to NAg is unlikely [14, 16, 18, 23], 
and yet, compelling scientific evidence in recent years 
has shown that bacteria can indeed adapt to the multi-
targeting toxicity [23–26]. Gunawan et  al. reported the 
growth of the environmental bacteria Bacillus sp. at the 
otherwise toxic NAg concentrations following prolonged 
exposures to the nanoparticle [24]. Such resistance devel-
opment has also been found in other bacteria, including 
the clinically relevant Escherichia coli and S. aureus [23, 
27], which is concerning as these ‘priority’ pathogens 
are known for their resistance to multiple antibiotics, 
including those used as the last line of treatment. Resist-
ance to NAg has been associated with transient changes 
in cellular phenotypes (observable traits). For example, 
a strain of E. coli was found to increase its production 
of the primary flagella protein, flagellin, in the presence 
of the nanoparticle. This protein was shown to facilitate 
NAg aggregation and in turn, passivating the toxicity of 
the nanoparticle [25]. We have shown that S. aureus, can 
evolve gene mutations to develop stable resistance char-
acteristics, which is maintained even after discontinu-
ation of NAg exposure [23]. Resistance to NAg has also 
been linked to the presence of silver ion efflux systems, 
more specifically, the chromosomally encoded Omp/
EnvZ porin and Cus efflux mechanisms, as well as the 
Fig. 1 The inhibition of biofilm growth and eradication of established biofilm by NAg, ionic silver  (Ag+) and gentamicin (GM). A A schematic of 
biofilm growth stages. B Determination of the minimum inhibitory concentration (MIC, defined as the lowest concentration that resulted in no 
visual growth) of NAg (tested at 0.5–7 µg/mL),  Ag+ (0.5–7 µg/mL) and gentamicin (1–8 µg/mL) on P. aeruginosa general growth (24 h exposure 
at 37 °C). Red and blue boxes represent the untreated cell-only and the media-only controls, respectively. Effect of NAg,  Ag+ and GM on C P. 
aeruginosa biofilm formation (24 h exposure, 37 °C), determining the minimum biofilm inhibitory concentration (MBIC, defined as the lowest 
concentration that caused ≥ 80% biofilm growth inhibition) and on D grown P. aeruginosa biofilm (24 h exposure, 37 °C), determining the minimum 
biofilm eradication concentration (MBEC, defined as the lowest concentration that caused ≥ 80% reduction of pre-formed biomass). Biofilm 
biomass is expressed as % relative to the cell-only control (no antimicrobial agent, 0 µg/mL). Error bars represent SEM (standard error of the mean) 
of three biological replicates (experiments with independent bacterial inocula from three isolates and different antimicrobial preparations, each 
with three technical replicates). * indicates statistically significant inhibition and eradication effects with p > 0.05 (not significant, ns), p < 0.05 (*), 
p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****), relative to the cell-only control
(See figure on next page.)
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plasmid-encoded Sil efflux mechanisms [28]. Research 
inquiries into the nanoparticle resistance phenomena 
is still growing at this stage, with all studies, to the best 
of our knowledge, focused on the free-living planktonic 
bacterial growth. Bacteria, however, rarely exist as free-
living entities and the possibility of NAg adaptation phe-
nomena in the biofilm form of growth remains entirely 
unexplored. While quite a number of studies have shown 
the efficacy of NAg on bacterial biofilms [12, 13, 29–38], 
understanding the long-term impact of the nanoparticle 
exposures on the unique community growth is important 
[1, 3, 39]. The knowledge of adaptation phenomena in 
biofilms can inform strategies to control the most threat-
ening form of pathogenic growth.
Herein, our study focused on Pseudomonas aeruginosa 
biofilms, by assessing the biofilm growth inhibition and 
eradication activity of NAg, in comparison to ionic silver 
and a model antibiotic. An estimated 1.7 million annual 
cases of nosocomial infections have been linked to bio-
film growth, including those by P. aeruginosa, incurring 
a $94 billion healthcare cost per year, in the USA alone 
[40]. P. aeruginosa biofilms have been found growing 
on ventilators, causing pneumonia in patients, as well 
as in cystic fibrosis lungs, a major cause of mortality in 
CF patients [41, 42]. When growing as a biofilm, P. aer-
uginosa synthesizes three types of EPS polysaccha-
rides; alginate, Psl and Pel as matrix barrier to protect 
the bacterial biomass from antibacterial agents [43–45]. 
P. aeruginosa is also known to take up resistance genes 
through cell-to-cell transfer of mobile genetic elements, 
with the phenomena being linked to the bacterium rela-
tively high frequency of drug resistance [39, 46, 47]. Here, 
we explored the effect of long-term NAg exposures, in 
comparison to ionic silver and an antibiotic, assessing 
the potential development of adaptation mechanisms in 
P.aeruginosa biofilms. It is important to note that while 
there are some shared mechanisms, NAg in general 
exhibit different antibacterial activity when compared 
to ionic silver. For example, one study reported rapid 
stimulation of lethal cellular oxidative stress in Bacillus 
subtilis upon exposure to the nanoparticle, which is in 
contrast to the reactive oxygen species (ROS)-independ-
ent ionic silver toxicity mechanism on the bacterium 
[16]. Other study detected peptide dephosphorylation in 
NAg-treated E. coli and Salmonella typhi samples, while 
being absent in the ionic silver-treated samples [48]. The 
dephosphorylation is thought to inhibit cellular signalling 
in metabolic pathways, further linked to the observed 
growth inhibition. The present study found that, while 
the silver agents exhibit potent antibacterial effects on 
P. aeruginosa biofilm, the bacterium evolved persistence 
characteristics following prolonged exposures, highlight-
ing the risks of long-term silver treatments.
Results and discussion
Biofilm inhibition and eradication activity of NAg,  Ag+ 
and gentamicin
We first studied the toxic effects of NAg (finely dispersed 
dTEM = ∼2  nm silver particulates on inert 30  nm  TiO2 
support) [14],  Ag+ (supplied as  AgNO3) and GM (gen-
tamicin sulfate) on P. aeruginosa. The MIC, defined as 
the minimum concentration to inhibit bacterial growth, 
was observed at 3 and 2 µg/mL for NAg and  Ag+, respec-
tively (Fig. 1B). For P. aeruginosa, the NAg MIC has been 
reported to range between 0.59 to 50  µg/mL [12, 25, 
26, 37, 49–52]. This is due to variations in the physico-
chemical characteristics, such as size, shape, and pres-
ence of surface moieties, which significantly affect the 
antibacterial activity of the nanoparticle [53–55]. Our 
NAg MIC is in accordance with the lower range of the 
published MICs, which is most likely due to the relatively 
small particle size. Our  Ag+ MIC is also consistent with 
those reported in the literature (0.002–1.88  µg/mL) for 
P. aeruginosa [26, 38, 56, 57]. Also seen in the present 
work, the generally greater antibacterial activity of  Ag+ 
than NAg at equivalent silver concentration, which is 
thought to relate to the unique microbiological activities 
of the different silver species [16, 58]. Numerous studies 
have reported the higher extent of toxicity of  Ag+ (free 
ions, when not locked in complexes) on bacteria than 
nanoparticulate silver [28, 59–61]. The MIC of GM was 
herein observed at 7 µg/mL, again, within the 2—32 μg/
mL MIC range reported by earlier studies [52, 62–66]. 
Unlike the multi-targeting NAg and  Ag+, GM typically 
works by binding to the 30S ribosomes in bacteria, in 
turn, inhibiting protein synthesis [67–69]. The antibac-
terial mechanisms of NAg and  Ag+ are complex, which, 
among others, include cell envelope perforations, inhibi-
tion of enzymes and disruptions of structural proteins, as 
well as DNA damages [16, 18, 28, 59]. It is therefore rea-
sonable to suggest that, relative to the antibiotic, it would 
be more challenging for bacteria to cope with NAg and 
 Ag+ toxicity [70].
We studied the anti-biofilm effects of the antibacte-
rial agents by determining the minimum concentrations 
to inhibit biofilm growth (MBIC), as well as, the mini-
mum concentrations to eradicate an established biofilm 
(MBEC). Exposure of P. aeruginosa to increasing NAg 
and  Ag+ concentrations saw a dose-dependent inhibition 
of biofilm growth, with the MBIC in this case defined as 
the minimum concentration that caused ≥ 80% growth 
inhibition relative to the cell-only control growth. The 
MBIC was observed at 3 µg/mL for NAg (Fig. 1C), which, 
as with the MIC, is consistent with the lower range pub-
lished concentrations for P. aeruginosa (0.5  µg/mL to 
1000 mg/mL) for smaller particle sizes [30, 33, 38, 49–51, 
71, 72]. It is important to note that larger NAg particles 
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have been reported to associate with higher MBICs [30, 
38, 50, 71], indicating the significance of particle size 
in the anti-biofilm activity. The MBIC of  Ag+ was 2 µg/
mL (only limited number of  Ag+ MBIC studies have 
been carried out at this stage for P. aeruginosa, includ-
ing the ~ 10 µg/mL MBIC reported by Lemire et al.[73]). 
Our NAg and  Ag+ MBICs are similar to their MICs and 
it is reasonable to suggest that these inhibitory concen-
trations should be within similar ranges, as biofilm for-
mation would not occur if the general bacterial growth is 
inhibited [74, 75]. Earlier studies have linked the biofilm 
inhibition effect of silver to down-regulation of genes 
that are involved in biofilm formation as well as bacte-
rial motility, and this is particularly evident with sub-
inhibitory bacterial exposure to NAg [50]. With GM, 
a dose-dependent gradual decrease in biofilm growth 
was observed, with the MBIC determined at 15–20  µg/
mL. Next, we studied the capability of these antibacte-
rial agents to eradicate established biofilms. The MBEC is 
defined as the minimum concentration that caused ≥ 80% 
biomass reduction of a pre-formed biofilm relative to the 
cell-only control. As shown in Fig. 1D a dose-dependent 
biofilm eradication effect was seen for all agents, with 
an MBEC of 5 µg/mL for both NAg and  Ag+. The NAg 
MBEC is consistent with the lower range of previously 
published concentrations (1.25 to 50 µ/mL) for smaller 
particle sizes [29, 30, 33, 35, 50]. The  Ag+ MBEC is lower 
than the previously published values of 7 and 12.5 µg/mL 
(only limited number of  Ag+ MBEC studies have been 
carried out for P. aeruginosa)[29, 73]. It has been hypoth-
esized that  Ag+ ions would pass through the surface por-
ins that are present in biofilm cells [12, 38], while NAg, 
due to their solid particulate nature and larger size, may 
be less able to penetrate the biofilm matrix. In our study 
however, both silver were associated with similar MBECs. 
Although still unclear, the observations are in line with 
Park et al. reporting a comparable eradication activity of 
NAg and  Ag+ on bacterial biofilms under stirring condi-
tions, which was indicated to enhance the biosorption 
of NAg into the biomass, rendering the nanoparticle as 
effective as the ion [76]. For GM, although a reduction in 
biofilm biomass was observed at concentrations starting 
from 10  µg/mL, the ≥ 80% biomass reduction threshold 
was only seen at the 100–150  µg/mL range, considered 
herein as the MBEC. The GM MBEC for P. aeruginosa 
has been previously reported at 16 µg/mL [77], and the 
difference could be related to the different strains used 
(ATCC 27,853 in their study). Overall, our MIC, MBIC 
and MBEC data has shown that NAg,  Ag+ and GM are 
capable of both inhibiting biofilm formation as well as 
eradicating established biofilms of P. aeruginosa. How-
ever, as next described, the bacterium is developing adap-
tation mechanisms upon prolonged exposures and that 
these mechanisms are unique for the silver and antibiotic.
Adaptation responses of biofilm‑forming P. aeruginosa 
to NAg,  Ag+ and gentamicin
The ability of P. aeruginosa to adapt and evolve resist-
ance was studied with a 30 d exposure experiment by 
serially passaging (sub-culturing every 24  h) the bac-
terium in increasing concentrations of NAg,  Ag+ and 
GM (Fig.  2A). The prolonged exposure saw progressive 
shifts in the highest antimicrobial dosage at which P. aer-
uginosa could proliferate (Fig.  2B). For NAg, starting at 
sub-MIC dosage (1 µg/mL) at day 1, the bacterium could 
grow at increasing nanoparticle dosages, reaching a max-
imum at 9 µg/mL (threefold MIC) at day 30. Similarly, for 
 Ag+, P. aeruginosa was able to proliferate when subjected 
to increasing silver dosage from sub-MIC (0.50 µg/mL) to 
6 µg/mL (threefold MIC) at day 30. By comparison, the 
exposure to GM resulted in a drastic increase, starting at 
sub-MIC dosage and reaching 750 µg/mL (100-fold MIC) 
at day 30.
The observed growth at increasing concentrations 
of NAg,  Ag+ and GM during the passaging experiment 
indicated that the bacterium has developed adapta-
tion responses. Bacteria have been known to adapt to 
elevated levels of antimicrobials via a number of differ-
ent mechanisms. A resistance trait is developed when 
a higher dosage of the antibacterial agent is required to 
inhibit the growth, characterized by an MIC increase, 
while a tolerance or persistence manifest when it takes 
longer for the agent to kill the bacterial population, 
with no change in the MIC [78]. To first determine if P. 
aeruginosa has developed resistance, the passaged cul-
tures were sampled from the mid-point of the passaging 
course (at between 12 and 17 d), as well as at the end of 
the experiment, and were re-exposed to the respective 
antimicrobials, to look for a minimum two-fold increase 
in the MIC, MBIC and MBEC. For the general growth, 
there was no increase in the MIC of both NAg (3  µg/
mL) and  Ag+ (2  µg/mL) for the mid-point as well as 
(See figure on next page.)
Fig. 2 Evolutionary adaptation of P. aeruginosa to NAg, ionic silver  (Ag+) and gentamicin (GM) through serial passaging. A A schematic of the 
passaging experiment. Starting at the respective sub-MIC levels of each agent, the biofilm-forming bacterium was continuously exposed to 
progressively increasing concentrations of NAg,  Ag+ and GM for 30 d via sub-culturing every 24 h. The passaging experiment also included a 
cell-only passaged culture (no antibacterial agent). B The increasing shifts in the highest dosage of NAg,  Ag+ and GM at which the bacterium 
could proliferate, with the table detailing the shifts as MIC fold-increase for each agent. Two biological replicates were performed for the passaging 
experiments, each with three technical replicates. Refer to Additional file 1: Figure S1 for the second biological replicate data
Page 6 of 17Mann et al. J Nanobiotechnol          (2021) 19:291 
Fig. 2 (See legend on previous page.)
Page 7 of 17Mann et al. J Nanobiotechnol          (2021) 19:291  
end-point passaged cultures relative to the wild-type P. 
aeruginosa. For GM, a 40 to 60-fold MIC increase (from 
7 to 300–400  µg/mL) and 200 to 300-fold (from 7 to 
1500–2000 µg/mL) were seen for the mid-passaged and 
end-passaged cultures, respectively. Similarly, biofilm 
inhibition studies revealed comparable MBIC of NAg 
and  Ag+ for the mid-passaged (NAg at 4 µg/mL and  Ag+ 
at 2 µg/mL) and end-passaged (NAg at 3 µg/mL and  Ag+ 
at 2 µg/mL), as those of the wild-type strain. In contrast, 
for GM, the ≥ 80% growth inhibition threshold shifted to 
1000 µg/mL for both the mid-passaged and end-passaged 
cultures (Fig. 3A, B) (note that in other independent rep-
licates of GM-passaged cultures, the inhibition threshold 
were only observed at the highest test-able concentration 
of 100 mg/mL, reaching the solubility limit of the antibi-
otic, Additional file 1: Figures S1 and S2). For the biofilm 
eradication, the MBEC of NAg for the mid- and end-
passaged cultures were 2 µg/mL, even lower than that of 
the wild-type strain at 5 µg/mL (Fig. 3C, D). The MBEC 
of  Ag+ for both passaged cultures (2  µg/mL) were also 
lower than the wild-type culture. For GM, essentially no 
biofilm eradication was observed even at 100 mg/mL, for 
both the mid- and end-passaged cultures.
Taken together, our MIC, MBIC and MBEC assess-
ments of the antibacterials on the passaged cultures indi-
cate that P. aeruginosa did not develop resistance to the 
silver agents, with still similar minimum concentrations 
required to inhibit the biofilm formation or to eradi-
cate grown biofilm, as the wild-type strain. Instead, the 
bacterium was found to exhibit other types of adapta-
tion as a result of the prolonged exposures, which will 
be described in the next section. In the case of NAg, the 
findings are in contrast to the only earlier evidence of 
potential resistance development in P. aeruginosa. Pan-
acek et al. reported a 32-fold MIC increase following a 20 
d exposure to increasing NAg concentrations [25]. The 
discrepancies with the present work could result, at least 
in part, from the different approach of the prolonged 
exposures, whereby a 2-to-3 d cell culturing in medium 
only (no NAg) was included by Panacek et al. in between 
each 24  h passaging sequence, while herein, the bacte-
rium was constantly exposed to NAg. To the best of our 
knowledge, the previous work did not explore the poten-
tial for adaptation responses in the biofilm form of P. aer-
uginosa growth. In the case of  Ag+, Muller and Merrett 
reported that P. aeruginosa is intrinsically resilient to 
the ion with an MIC of 20  µg/mL, which is thought to 
associate with the bacterium’s ability to produce pyocy-
anin, a redox molecule that can reduce  Ag+ to  Ag0 par-
ticulates, thereby lowering the toxicity [79]. The work 
however, did not investigate the potential of the bacte-
rium to develop adaptation during prolonged exposure. 
Here, the GM-passaged P. aeruginosa developed resist-
ance with significant increase in MIC, MBIC and MBEC, 
and consistent with earlier reports, the resistance traits 
developed rapidly [80, 81]. Resistance to GM and other 
aminoglycosides typically result from the activity of spe-
cific aminoglycoside-modifying enzymes, which can lead 
to the inactivation of aminoglycosides, rendering them 
unable to recognise their 30S ribosomal target in bacteria 
[82]. Other studies have linked the resistance mechanism 
to a reduced cell envelope permeability, while some have 
suggested the role of an efflux mechanism (the MexXY 
system) [82–84]. The development of the GM-resistant 
culture in the present work verifies our sequential pas-
saging methodology for the evolutionary study of adapta-
tion responses.
Persistence mechanism to NAg and  Ag+
Since it was clear that the silver exposure did not 
result in the development of resistance, we next tested 
whether the passaged strains were demonstrating tol-
erance or persistence. More specifically, tolerance is 
the ability of bacterial population in general to survive 
longer in the presence of antimicrobials as a result of 
a slower killing rate, whereas, persistence has the addi-
tional attribute of affecting only a subpopulation of 
cells, the so-called ‘persisters’, to survive exposure to 
an otherwise lethal antibacterial concentration. This 
slower killing trait is characterized by an increase in 
the minimum exposure time required to kill 99% and 
99.99% of the population, referred to as  MDK99 and 
 MDK99.99, for tolerance and persistence, respectively 
[78]. Time-kill studies were performed to determine 
any increase in these parameters for NAg and  Ag+ for 
the passaged cultures relative to the wild-type strain.
Exposure of the NAg- and  Ag+-passaged cultures 
to the respective silver species (at 1.5 × MIC dosages) 
resulted in rapid killing of both bacterial populations 
in the first 30 min. The rapid killing was followed by a 
Fig. 3 Post long-term exposure changes in the MBIC A, B and MBEC C, D of NAg,  Ag+ and gentamicin (GM) on the respective mid-point passaged 
A, C and end-point passaged B, D strains (24 h exposure, 37 °C). Biofilm biomass is expressed as % relative to the cell-only control (no antimicrobial 
agent, 0 µg/mL). Error bars represent SEM (standard error of the mean) of three biological replicates (experiments with independent bacterial 
inocula from three isolates and different antimicrobial preparations, each with three technical replicates). *Indicates statistically significant biofilm 
growth inhibition A, B and eradication of established biomass C, D with p > 0.05 (not significant, ns), p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) and 
p < 0.0001 (****), relative to the cell-only control. The MBIC and MBEC studies of the second biological replicate of the passaging experiment are 
presented in Additional file 1: Figure S2
(See figure on next page.)
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slower killing of the passaged culture cells when com-
pared to the wild-type. This biphasic cell-killing pro-
file is consistent with persistence (Fig.  4A, B) [78]. 
The killing kinetics of the NAg-passaged culture saw 
a longer  MDK99.99 relative to the wild-type, with no 
change in  MDK99, indicating the development of per-
sistence in the passaged culture (Fig.  4A). Similarly, a 
longer  MDK99.99 and no change in  MDK99 was also 
seen for  Ag+ (Fig. 4B). Persistence develops when bac-
teria undergo non-mutational variations such that a 
sub-population of cells are capable of surviving bacte-
ricidal concentrations of an agent for longer than the 
main population [78, 85–87]. These dormant, meta-
bolically inactive cells are not considered ‘resistant’, as 
resistance is the ability to both survive and proliferate 
at an otherwise toxic concentration of an agent [78, 85]. 
Many studies have linked persistence to the formation 
of small colony variants (SCVs) in a bacterial popula-
tion [88, 89]. Our work have shown that prolonged 
exposures of P. aeruginosa to NAg and  Ag+ had indeed 
resulted in the formation of persister cells in the form 
of SCVs (Fig. 4D–G). While the variants were found in 
the wild-type strain, their abundance were ~ 25% higher 
in both the NAg- and  Ag+-passaged strains (Fig. 4H, I). 
Further, in addition to their smaller colony size, SCVs 
often show increased exopolysaccharide production 
and enhanced biofilm formation [90]. The latter was 
also indicated in the present study, with both the NAg- 
and  Ag+-passaged strains forming an at least two-fold 
higher biofilm biomass than the wild-type strain (Addi-
tional file 1: Figure S3).
To the best of our knowledge, this is the first evidence 
for the development of persistence phenotype in bac-
teria in response to silver antibacterials. Studies have 
shown that oxidative stress, one of the major toxicity 
mechanisms for silver, can trigger a persistence pheno-
type and formation of SCVs [91–94]. Further, persister 
cells have been associated with an increased expression 
of efflux pumps [93], the latter were already seen in bac-
teria with an increased resilience to silver  (Ag+) [91]. A 
link has also been established between the formation of 
SCVs to the increased expression of the secondary mes-
senger molecule cyclic-di-GMP in P. aeruginosa, which 
regulates many processes involved in virulence as well 
as the transition between planktonic to biofilm growth 
[95]. Finally, studies have shown that persister cells can 
resume growth once the antibacterial exposure ceases 
[87, 96, 97]. Indeed, we observed normal colony growth 
following sub-culturing of the SCVs, from both the 
NAg- and  Ag+-passaged cultures, on antimicrobial-free 
medium (Fig. 4J, K). Thus, it is apparent that silver expo-
sure selects for persister cells in the population as well as 
SCVs, which is linked to survival of P. aeruginosa in the 
presence of the antibacterials.
Biofilm‑associated silver and antibiotic cross‑resistance
Finally, we studied the evolved GM resistance for the 
possibility of cross-resistance to the silver antibacteri-
als. The MIC and MBIC of NAg and  Ag+ on the GM-
resistant P. aeruginosa was found at 2 and 1  µg/mL, 
respectively (Fig.  5A), and these were lower than those 
observed for the wild-type strain (NAg at 3  µg/mL and 
 Ag+ at 2  µg/mL). The data show that the GM-resistant 
strain is more sensitive to both NAg and  Ag+. This could 
relate to the known modification of the 30S ribosomal 
subunit linked to the GM resistance [98]. However, how 
that would lead to the enhanced silver sensitivity is not 
currently clear. Further silver studies on an already grown 
GM-resistant P. aeruginosa biofilm yields an interest-
ing contrast. As shown in, the MBEC were considerably 
higher with no significant biofilm eradication observed 
even at 10 µg/mL, for both silver formulations (Fig. 5B). 
Note that the MBEC was at 5  µg/mL NAg and  Ag+ for 
the wild-type biofilm. The findings indicate cross-resist-
ance traits to NAg and  Ag+ of the GM-resistant strain 
when the bacteria have already formed a biofilm, but 
apparently not prior, when the population were still in 
their free-living planktonic form. The cross-resistance 
phenomena were most likely associated with a hindered 
biofilm penetration of the silver antibacterials. Using 
multiphoton microscopy, we detected presence of NAg at 
up to 10 µm depth in the GM-resistant biofilm samples, 
(See figure on next page.)
Fig. 4 Persistence to silver and the formation of small colony variants (SCVs) in P. aeruginosa. Killing kinetics of A NAg-passaged and B 
 Ag+-passaged P. aeruginosa in comparison to the wild-type strain. The bacterium was first grown to early exponential phase and exposed to 
the silver antibacterials at their respective 1.5 × MIC dosages (4.5 µg/mL for NAg, 3 µg/mL for  Ag+). The  log10 decrease in cell population was 
determined relative to population at time 0 (as colony forming units). Refer to Additional file 1: Figure S3A, B for the biological replicate of the killing 
kinetics and to Additional file 1: Figure S3C, D for the two biological replicates of the killing kinetics of the strains isolated from the second biological 
replicate of the NAg and  Ag+ passaging experiments. C Representative image of normal colonies of non-silver-treated wild-type, NAg-passaged 
and  Ag+-passaged strains, D, E The colonies from the wild-type and NAg-passaged strains after 60 min exposure to NAg (at 1.5 × MIC dosage), F, G 
The colonies from the wild-type and  Ag+-passaged strains after 60 min exposure to  Ag+ (at 1.5 × MIC dosage). Note the occurrence of SCVs with 
the silver treatments. H, I The SCVs quantification in the silver-treated samples is presented as % relative to the total number of colonies and shown 
is the data from the two biological replicate of the NAg and  Ag+ passaging experiments. *Indicates statistically significant higher occurrence of 
SCVs with p < 0.01 (**) and p < 0.001 (***), relative to the wild-type strain. The growth of normal colonies resumed upon sub-culturing of the SCVs 
from the (J) NAg-passaged and (K)  Ag+-passaged strains, on antimicrobial-free medium
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while the nanoparticles were still present at up to 15 µm 
depth in the wild-type biofilm (Fig. 5C, Additional file 1: 
Figure S4). Although the exact mechanism remains to be 
explored, the hindered penetration is thought to result, 
at least in part, from changes in the biofilm EPS matrix 
composition. We observed the formation of cell aggre-
gates in the GM-resistant biofilm, while these ‘clumps’ 
of cells were absent in the wild-type biofilm (Fig.  5C). 
Earlier studies have noted similar phenotype in a P. aer-
uginosa strain that overproduces one of the major bio-
film polysaccharide matrix components, the Psl, in turn, 
enhancing cell-to-cell adhesion [99].
Conclusions
In summary, the work reported unique silver adaptation 
mechanisms with pathogenic biofilm-forming bacterium 
that have not been previously reported with planktonic 
bacterium studies. While silver nanoparticles (NAg) 
and ionic silver  (Ag+) are effective in inhibiting and 
eradicating P. aeruginosa biofilm growth, we found evi-
dence of persister cells as a mechanism of survival upon 
repeated NAg and  Ag+ exposures. Our work highlights 
for the first time the possibility of recurrent infections 
with prolonged silver treatments, with persister cells 
and the associated small colony variant (SCV) pheno-
type. As expected, the biofilm-forming bacterium rap-
idly developed a high level of resistance to the antibiotic 
gentamicin (GM). We further found that the antibiotic-
resistant strain was in fact sensitive to NAg and  Ag+ 
when in the planktonic phase, with both silver formula-
tions capable of inhibiting the biofilm growth, however, 
not when the resistant strain was already forming biofilm. 
Both NAg and  Ag+ were ineffective in eradicating grown 
GM-resistant biofilm, with the apparent silver/antibiotic 
cross-resistance being linked to the hindered penetration 
of the silver nanoparticles. Taken together, the findings 
inform strategies on the control of pathogenic biofilm 
growth. NAg (and  Ag+) are not recommended for pro-
longed treatments of biofilm infection, whereas both 
silver formulations are effective in inhibiting antibiotic-
resistant biofilm growth, although not on established bio-
mass. Future studies should explore the NAg adaptation 
mechanisms of other important pathogenic species in 
their biofilm form of growth, as well as the potential for 
the nanoparticle as an alternative to combat the antibi-
otic-resistant growth.
Materials and methods
Bacterial strain and preparation of bacterial inoculum 
and antibacterial agents
Pseudomonas aeruginosa PAO1, a derivative of the 
PAO strain first sourced from the wound of an Austral-
ian burn victim, was used in this study due to its innate 
ability to form biofilms [100]. Cultures were grown in 
cation adjusted Mueller–Hinton agar or broth (CAMH, 
BD, Australia). To prepare the bacterial inoculum for 
each experiment, an overnight culture was grown at 
37  °C, 250  rpm orbital shaking for 16–17  h, then pre-
conditioned by 1/100 dilution with fresh CAMHB 
and incubated for a further 2  h at 37  °C, 250  rpm to 
reach ~  107 cfu/mL bacterial concentration. This process 
rendered the culture to enter the log-phase, whereby the 
cells are in their most metabolically active state, to test 
the effects of antibacterial agents [101].
Nanosilver (NAg) with  Ag2O finely dispersed onto 
inert  TiO2 support was prepared by flame spray pyroly-
sis at the University of New South Wales [24]. For subse-
quent use in antibacterial studies, NAg was sterilized by 
gamma-irradiation with Co-60 source at 6.7 Gy/min for 
1 h (mean = 402 Gy/h) at the Australian Nuclear Science 
and Technology Organization. Silver nitrate  (AgNO3, 
Merck & Co., Inc., USA) dissolved in Milli-Q water 
served as ionic silver  (Ag+) source and gentamicin (GM) 
was supplied as gentamicin sulfate (Sigma-Aldrich, USA) 
dissolved in Milli-Q water. Immediately before the exper-
iments, NAg suspension was homogenised by ultrasoni-
cation (Vibra-cell, Sonics & Materials, Inc.) at 50% output 
control for 20 s. Experiments with NAg and  AgNO3 were 
performed under dark conditions to render the  TiO2 sup-
port of the nanoparticles photocatalytically inactive and 
to prevent  Ag+ reduction to  Ag0, respectively.
Fig. 5 Biofilm-associated cross-resistance of gentamicin (GM)-resistant strain to silver. A Inhibition of biofilm growth of P. aeruginosa GM-resistant 
strain by NAg and  Ag+ (24 h exposure, 37 °C). B Eradication of established biofilm of GM-resistant strain by NAg and  Ag+ (24 h exposure, 37 °C). 
Biofilm biomass is expressed as % relative to the cell-only control (no antimicrobial agent, 0 µg/mL). Error bars represent SEM (standard error of the 
mean) of three biological replicates (experiments with independent bacterial inocula from three isolates and different antimicrobial preparations, 
each with three technical replicates). *Indicates statistically significant inhibition and eradication effects with p > 0.05 (not significant, ns), p < 0.05 
(*), p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****), relative to the cell-only control. C Penetration of NAg particle (aggregates) in wild-type and 
GM-resistant P. aeruginosa biofilms. Biofilm biomass (green) were exposed to NAg at 20 × MIC dosage (3 h, 37 °C) and sectional z-stack depth 
images were acquired using multiphoton microscope. The second harmonic generation and hyper Rayleigh scattering signals of NAg particles 
(pink) were used to detect their presence in the biofilms. Scale bar = 20 µm. Refer to Additional file 1: Figure S4 for the NAg and  Ag+ biofilm 
inhibition and eradication studies, as well as the multiphoton biofilm-nanoparticle imaging of the GM-resistant strain obtained from the second 
biological replicate of the passaging experiment
(See figure on next page.)
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Determination of minimum inhibitory concentration 
(MIC), minimum biofilm inhibitory (MBIC) and eradication 
concentration (MBEC)
MIC was determined following the broth microdilution 
method by the Clinical and Laboratory Standard Insti-
tute with modifications. Briefly, the bacterial inoculum 
was exposed to various concentrations of the antibacte-
rial agents in CaMH broth in a 96-well microtiter plate 
(Corning, USA) at 160 µL total volume, with a cell-only 
and broth-only controls. Plates were sealed with AeraSeal 
(Excel Scientific, USA) and incubated in a static humidi-
fied incubator at 37 °C for 24 h. The MIC was determined 
visually as the lowest antibacterial concentration with 
no observable growth. The experiments were performed 
in three biological replicates, each with three technical 
replicates.
For MBIC studies, similar exposure systems were set 
up. After the 24 h exposure in a static humidified incuba-
tor at 37  °C, the culture wells were washed three times 
with phosphate buffered saline (PBS) using an auto-plate 
washer (Bio-Tek, ELx405, USA) to remove any planktonic 
cells, followed by staining of the biofilm biomass with 
0.2% (v/v) crystal violet (CV) at room temperature for 
45 min on a plate shaker at ~ 75 rpm (Bio-line, Edwards 
Instrument Company, AUS). The biomass was then 
washed three times with PBS, followed by a de-staining 
step with 33% (v/v) acetic acid for 20 min at room tem-
perature at ~ 75  rpm to release any biofilm-bound CV 
into the solution. The absorbance was measured at 
595 nm in a microplate reader (Tecan Infinite M200 Pro). 
The MBIC was herein defined as the lowest antibacterial 
concentration that caused ≥ 80% growth inhibition rela-
tive to the cell-only control.
For MBEC studies, biofilms were first grown in a 
96-well plate from 80 μL bacterial inoculum and incu-
bated in a humidified incubator at 37  °C for 24  h. The 
culture wells were then washed three times with PBS to 
remove any planktonic cells. The pre-formed biofilms 
were exposed to various concentrations of the antibacte-
rial agents (160 µL total volume) for 24 h at 37  °C. The 
biofilm biomass was stained with CV and destained 
with acetic acid as previously described. The MBEC was 
herein defined as the lowest antibacterial concentration 
caused ≥ 80% biomass reduction of a pre-formed biofilm 
relative to the cell-only control.
Evolutionary adaptation to NAg,  Ag+ and gentamicin
To investigate the potential for P. aeruginosa to evolve 
adaptation to NAg,  Ag+ and GM, the bacterium was 
serially passaged (via sub-culturing every 24 h) for 30 d 
in 24-well microtiter plates (Corning, USA) in the pres-
ence of progressively increasing concentrations of the 
antibacterial agents in CaMH broth, starting at their 
respective sub-MIC doses. At day 1 for example, the bac-
terial inoculum at 1/10 dilution was exposed to 0.25 × , 
0.5 × , 1 × and 1.5 × MIC of the agents at 1 mL total vol-
ume, with a cell-only and broth-only controls (Fig.  2A). 
Three technical replicates were set up for each of the 
antibacterial dosages. Following 24 h exposure at 37  °C, 
150 rpm, cultures from the highest antibacterial exposure 
concentration that allowed visible growth were passaged 
at 1/10 dilution to the next higher antibacterial dosage 
range, for instance, at 0.5 × , 1 × , 1.5 × and 2 × MIC. 
The passaging experiments were carried out with two 
independent biological replicates. The MIC, MBIC and 
MBEC of NAg,  Ag+ and GM on the mid-point (between 
12 to 17 d) and end-point (30 d) passaged strains were 
determined as previously described, to confirm for resist-
ance development (a minimum of two-fold increase 
relative to the wild-type strain). The antibiotic GM is to 
also serve as a reference for validation of the passaging 
experiment as P. aeruginosa has been known to develop 
resistance to GM more rapidly when compared to many 
antibiotics [80, 81].
Time‑kill assay
Early-exponential phase cultures of the NAg- and 
 Ag+-passaged strains were exposed to the respective 
silver antibacterials at their 1.5 × MIC dosages at 37  °C, 
with samples taken every 30  min for 2  h. The samples 
were serially diluted and plated on CaMH agar and incu-
bated for 24 h at 37 °C for growth of colonies. The time-
kill profiles were obtained by plotting the fraction of 
surviving cells at each time point (as cfu (colony forming 
units)/mL) relative to the time zero cell population. Two 
independent time-kill biological replicates were carried 
out for each of the two biological replicates of the NAg- 
and  Ag+-passaged strains.
Fluorescence imaging of biofilms and NAg penetration
To establish the biofilms, a measured 200 µL of the 
bacterial inoculum was inoculated to a glass-bottomed 
Ibidi imaging well slide (DKSH, Aus) and incubated at 
37  °C for 18  h. NAg particles were then dosed to the 
biofilms at × 20 MIC dosage for 3  h. After exposure, 
the unabsorbed/unadsorbed particles were removed 
by three times PBS washing over the surface of the 
biomass. The biomass was stained with rhodamine b 
(200 µL, 5 µg/mL) for 5 min at 37 °C. Excess stain was 
removed and replenished with CaMH broth for imag-
ing. Imaging was performed with a multiphoton micro-
scope LSM 710 with Axio Observer Z1 (Carl Zeiss, 
Jena, Germany) equipped with a tunable titanium sap-
phire laser Mai Tai® (Spectra Physics, Mountain View, 
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CA, used at 6 mW laser power). Images were taken in 
the optical z-direction with 5 µm steps. The rhodamine 
b that stained the biomass was imaged at ex:800  nm 
two photon em:508–710 nm and the second harmonic 
generation and hyper Rayleigh Scattering signals of the 
NAg were imaged simultaneously in a separate channel 
at ex:800 em:370–420  nm and 26% laser power [102, 
103]. All samples were imaged in triplicates and repre-
sentative samples are shown.
Statistical analysis
Statistical analysis was performed using GraphPad 
Prism and the results were compared using a one-way 
analysis of variance (ANOVA), followed by Dunnett’s 
multiple comparison test, with a p value significance 
level set at < 0.05.
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